跳至主要内容
临床试验/DRKS00023031
DRKS00023031招募中不适用

A multicentre prospective longitudinal observational study to evaluate biomarkers and mechanistic principles in moderate to severe ulcerative colitis (UC) patients treated with different targeted therapies - ImmUniverse UC

niversitätskliniikum Schleswig-Holstein, Campus Kiel Klinik für Innere Medizin I für die deutschen Partner der multizentrischen Studie0 个研究点目标入组 270 人开始时间: 2020年9月29日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
270

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. Signed written Informed Consent
  • 2. Established diagnosis of ulcerative colitis with a minimum disease duration of 3 months
  • 3. Moderate to severe active UC, defined by Mayo Score = 6 including endoscopy score of = 2
  • 4. Indication to start any biological or small molecule agent (anti-TNF, anti- IL12/23, anti-integrin and JAK-inhibitors)
  • 5. In case of treatment with corticosteroid: stabile dose for at least 3 weeks prior to baseline, dosage = 20 mg prednisone
  • 6. Indication for colonoscopy for the assessment of disease activity as for standards of care and current guidelines
  • 7. Able to comply with the study procedures

排除标准

  • 1. Diagnosis of indeterminate colitis, microscopic colitis, ischaemic colitis, infectious colitis, radiation colitis
  • 2. Absolute contraindications to colonoscopy procedures, complication during previous endoscopy
  • 3. Bleeding disorders
  • 4. Indication for surgery for UC
  • 5. Legal incapacity
  • 6. Rectal topical therapy (enemas or suppositories) = 2 weeks prior to baseline
  • 7. Treatment with > 20 mg prednisone within 3 weeks prior to baseline
  • 8. anaemia (haemoglobin < 10 g/dl) at baseline
  • 9. Pregnant or breastfeeding women
  • 10. Any circumstances which could contradict a study participation and lead the Investigator to assess the patient as unsuitable for study participation for any other reason

研究者

发起方
niversitätskliniikum Schleswig-Holstein, Campus Kiel Klinik für Innere Medizin I für die deutschen Partner der multizentrischen Studie

相似试验